TRVI News and Press, Trevi Therapeutics Inc. From 11/13/22

Trevi Therapeutics, Inc. (TRVI) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Jennifer Good - President and CEO Lisa Delfini - CFO Conference Call Participants Annabel Samimy - Stifel Serge Belanger - Needham &...

Trevi Therapeutics press release ( NASDAQ: TRVI ): Q3 GAAP EPS of -$0.12 misses by $0.01 . Cash and cash equivalents of $66.57M Net loss: For the third quarter of 2022, the Company reported a net loss of $8.3 million, compared to a net loss of $7.3 million in the...

Trevi Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update PR Newswire Management to host a conference call and webcast today at 4:30 p.m. EDT NEW HAVEN, Conn. , Nov. 10, 2022 /PRNewswire/ -- Trevi Therape...

Trevi Therapeutics to Participate at the Stifel 2022 Healthcare Conference PR Newswire Fireside chat will be held on Wednesday, November 16, 2022 , from 3:35 p.m. to 4:05 p.m. EDT NEW HAVEN, Conn. , Nov. 8, 2022 /PRNewswire/ -- Trevi The...

Trevi Therapeutics to Report Q3 2022 Financial Results and Provide a Corporate Update on November 10, 2022 PR Newswire Conference call and webcast to be held at 4:30 p.m. EDT NEW HAVEN, Conn. , Nov. 3, 2022 /PRNewswire/ -- Trevi Therapeutic...

Trevi Therapeutics to Present Final Data from Phase 2 Trial of Oral Nalbuphine Extended Release for Chronic Cough in IPF at BTS' Winter Meeting PR Newswire Data from full set of subjects was statistically significant for the primary efficacy endpoint (p<0.0001) ...

/C O R R E C T I O N -- Trevi Therapeutics, Inc./ PR Newswire The news release "Trevi Therapeutics Announces Pricing of $[50 Million] Public Offering", issued 22-Sept-2022 by Trevi Therapeutics, Inc. over PR Newswire was erroneously and prematurely issued by PR Newsw...

Trevi Therapeutics Announces Pricing of $[50 Million] Public Offering PR Newswire NEW HAVEN, Conn. , Sept. 22, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing an investigational thera...

Trevi Therapeutics ( NASDAQ: TRVI ) on Thursday said it had commenced an underwritten public stock offering. Shares of the micro-cap clinical-stage biopharma fell 12.7% to $1.69 after the bell. TRVI expects to grant the underwriters a 30-day option to purchase shar...

Trevi Therapeutics Announces Proposed Public Offering PR Newswire NEW HAVEN, Conn. , Sept. 22, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy, Haduvio!...